USE OF METFORMIN WITH EMPHASIS IN HEART PATIENTS
DOI:
https://doi.org/10.5281/zenodo.5161771Abstract
Treatment with metformin is known to significantly improve glucose control in people with type 2 diabetes, with no weight gain and negligible risk of hypoglycemia. In addition, metformin treatment appears to be associated with a lower risk of cardiovascular disease and morbidity. Thus, we aimed to perform a systematic review regarding the use of metformin in the treatment of cardiac patients. This is a systematic review of the literature. To do so, the literature reference selection method was ProKnow-C. The PICO acronym question was: In cardiac patients, can the use of metformin contribute to the treatment of this group? The following uncontrolled terms were used to search the material: "cardiac abnormality", "cardiac treatment", "metformin in cardiac patients". Regarding the inclusion criteria, we included articles published in national and international languages, in the time interval 2010-2021 and that were freely available in the platforms of the National Library of Medicine U.S (NLM/PUBMED), ScienceDirect (Elsevier) and Scientific Electronic Library Online (SciELO). Although metformin is used as a form of treatment in several clinical cases, some authors still claim that there are worrisome results regarding the incidence of cardiovascular deaths. Due to the instability of the articles under analysis, it is suggested by the authors of this study that more clinical trials be carried out in order to consolidate the effects of this drug in patients with cardiovascular problems.
Downloads
References
Graham GG. Clinical pharmacokinetics of metformin. Clinical pharmacokinetics. 2011. 50(2): 81–98.
Branchtein L, Matos MCG. Farmacologia clínica: fundamentos da terapêutica reacional. 3. ed. Rio de Janeiro: Guanabara Koogan; 2004.
Bianchin MD, Blatt CR, Soares, A, Guerreiro ICK. Avaliação da qualidade de comprimidos de propranolol e enalapril distribuídos no sistema público de saúde em uma cidade do sul do Brasil. Ciência & saúde coletiva. Rio de Janeiro,2012 17(2):491-498.
Neto EMR, Marques LARV, Ferreira MAD, Lobo PLD, Girão Junior FJ, Camarão GC, Moraes MEA. Metformina: uma revisão da literatura. Revista Saúde e Pesquisa. 2015; 8(2): 355-362.
Ensslin L, Ensslin SR, Lacerda RTO, Tasca JE. ProKnow-C: Processo de análise sistêmica. Brasil: Processo técnico com patente de registro pendente junto ao INPI; 2010.
Santos MJF. Avaliação da qualidade de vida e do controlo glicémico em diabéticos tipo 1 com bomba infusora de insulina. Revista Portuguesa de Endocrinologia Diabetes e Metabolismo. 2009; 4: 1-22.
Dresch A. Metodologia Científica para Engenharia. Rio de Janeiro: Elsevier; 2019.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5): 336-341.
Li T, Rui P, 2, Nan M, Yue Y, Mai C. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 2021;20(1):1-12.
Cattadori G. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Res Clin Pract. 2019; 157;107835.
Vanita R, Aroda WC, Knowler JP, Crandall LP, Sharon LE. Metformina para prevenção do diabetes. Diabetologia. 2017; 60(9):1601-1611.
Hong J, Zhang Y, Lai S. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013; 36(5): 1304-1311.
Monami M, Candido R, Pintaudi B,Targher G, Mannuci E. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism & Cardiovascular Diseases. 2021; 31: 699 – 704.
Bergmark BA, Bhatt D, McGuire D. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation. 2019; 140(12):1004-1014.
Zheng SL, Roddick AJ, Aghar-Jaffar R. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. Jama. 2018;319(15):1580 - 91.
Boussageon R, Supper I, bejon-angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A metaanalysis of randomized controlled trials. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. PLOS Medicine. 2012; 9.
